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Abstract: We evaluated the efﬁ  cacy and safety of a1 - blocker doxazosin for treatment of lower 
urinary tract symptoms (LUTS) compatible with benign prostatic hypertrophy (BPH). Fourteen 
randomized controlled trials enrolled 6261 men, average age 64 years, who had moderately severe 
LUTS and ﬂ  ow impairment. Compared with baseline measures and placebo effect, doxazosin 
resulted in a statistically signiﬁ  cant improvement in both LUTS and ﬂ  ow. However, when 
compared with placebo, the average magnitude of symptom improvement (International Prostate 
Symptom Score [IPSS] improvement <3 points) typically did not achieve a level detectable by 
patients. Combined doxazosin and ﬁ  nasteride therapy improved LUTS and reduced the risk of 
overall clinical progression of BPH compared to each drug separately in men followed over 
4 years. Reported mean changes from baseline in the IPSS were –7.4, –6.6, –5.6, and –4.9 points 
for combination therapy, doxazosin, ﬁ  nasteride, and placebo, respectively. Combination therapy 
reduced the need for invasive treatment for BPH and the risk of long-term urinary retention. The 
absolute reductions compared with placebo were less than 4% and primarily seen in men with 
prostate gland volume >40 mL or PSA levels >4 ng/mL. Efﬁ  cacy was comparable with other 
a1–blockers. Withdrawals from treatment for any cause were comparable to placebo. Dizziness 
and fatigue occurred more frequently with doxazosin compared to placebo. 
Keywords: benign prostatic hypertrophy (BPH); doxazosin; a1-adrenoceptor antagonists; lower 
urinary tract symptoms; systematic review
Introduction
Benign prostatic hypertrophy (BPH) is a common condition that can result in bother-
some lower urinary tract symptoms (LUTS). These symptoms may be obstructive (weak 
urine ﬂ  ow, hesitancy, straining, incomplete emptying) or irritative (frequency, nocturia 
urgency) (Medina et al 1999). LUTS consistent with BPH are estimated to occur in over 
30% of men 65 years or older (Chapple 2001). Treatment costs in the US, exclusive of 
outpatient pharmaceuticals, exceeds $1 billion dollars and accounts for nearly 8 million 
physician visits annually (Wei et al 2004). Therapeutic strategies to alleviate LUTS are 
based on symptom severity, prostate characteristics, and physician or patient preference. 
These include minimally invasive surgical techniques, lifestyle modiﬁ  cation, herbal 
preparations and prescribed medications, and transurethral resection of the prostate 
(TURP) (AUA 2003).
Alpha1-adrenoreceptor antagonists (α1–blockers) are a primary medical approach 
to treating LUTS. α1–blockers commonly used to treat LUTS include doxazosin, 
terazosin, alfuzosin and tamsulosin. The goal of this review is to evaluate the efﬁ  cacy 
and adverse events of nonuroselective α1-blocker doxazosin for LUTS associated 
with BPH and its effectiveness and safety compared with other medical therapies, 
including α1-blockers and 5-alpha reductase inhibitors. Our review emphasizes results 
from randomized controlled trials. We also summarize ﬁ  ndings from a comprehensive 
review of treatment options for BPH prepared for the American Urological Association 
(AUA) (AUA 2003). Because LUTS is a chronic medical condition we assessed Clinical Interventions in Aging 2006:1(4) 390
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the effectiveness of doxazosin on preventing progression 
of disease long-term and tolerability as well as improving 
existing symptoms and ﬂ  ow measures.
Subjects and methods
Search strategy
This report is an update of a previously published systematic 
review (MacDonald et al 2004). MEDLINE was searched 
from 1966 to May 2006 combining an optimally sensitive 
Cochrane Collaboration search strategy with the MeSH 
headings ‘prostatic hyperplasia’, ‘LUTS’, and ‘doxazosin’, 
‘alpha-blockers’, ‘Adrenergic Alpha-Antagonists’, ‘alpha 
1-adrenoceptor’ or ‘alpha-1 blocker’ including all subheadings 
(Dickersin et al 1994). The Cochrane Library, the Cochrane 
Prostatic Diseases and Urologic Cancers Review Group 
specialized registry, and reference lists of identiﬁ  ed trials 
and reviews were also searched. No language restrictions 
were applied to the search.
Selection criteria
Studies were included if men had symptomatic BPH, subjects 
were randomly assigned to doxazosin or a control (placebo, 
pharmacologic, or surgical treatment), and study duration was 
at least 4 weeks. We also reviewed and summarized ﬁ  ndings 
from the AUA 2003 Clinical Treatment Guidelines for BPH 
report (AUA 2003). 
Data extraction and study appraisal
Two reviewers (Roderick MacDonald and Timothy Wilt) 
independently determined whether studies met inclusion 
criteria. Study and demographic characteristics, enrollment 
criteria, outcomes, adverse effects, and number and reasons 
for dropout were then extracted. Authors and pharmaceutical 
manufacturers were contacted in attempts to obtain missing 
or additional information. As a measure of methodological 
study quality, the quality of concealment of treatment 
allocation for randomization was determined based on the 
scale developed by Schultz (1 = poorest quality, 2 = unclear, 
3 = best quality) (Schultz et al 1995). We assessed blinding 
methods to the treatment, if intention-to-treat analysis was 
used, and the percent lost to follow up or withdrawn from 
study protocol.
Statistical methods 
The primary outcome measure was deﬁ  ned a priori to be 
improvement in urological symptoms as measured by a 
validated symptom score eg, International Prostate Symptom 
Score or AUA (IPSS). Secondary outcome measures included 
peak urine ﬂ  ow, global assessment of symptom severity, 
complications associated with long-term progression of BPH 
(clinical progression measured by a 4-unit change in symptom 
score, need for invasive treatment such as prostatectomy, laser 
or microwave therapy, and urinary retention), adverse effects, 
and the incidence of withdrawals from treatment or participants 
lost to follow up. 
Percentage improvements from baseline for treatment and 
control were calculated for the primary efﬁ  cacy outcomes. 
If feasible, efﬁ  cacy and adverse event data were pooled and 
analyzed in the Cochrane Collaboration Review Manager 
(RevMan 4.2, Cochrane Collaboration, Oxford, UK) software 
(CC 2001). Weighted mean differences (WMD), the difference 
between treatment and control pooled means at endpoint, 
along with 95% conﬁ  dence intervals (CI) were calculated for 
continuous variables. Relative risk ratios (RR), comparing 
study intervention subjects with control subjects and their 
95% CI were calculated for categorical adverse event and 
withdrawal data. A ﬁ  xed-effects model was used if there was 
no evidence of heterogeneity between the studies, based on 
the chi-square test for heterogeneity (DerSimonian and Laird 
1986). Previous work has established levels of symptom score 
change that are noticeable to patients based on their baseline 
symptom severity (Barry et al 1995). Therefore, we also 
assessed whether mean symptom improvements compared 
with placebo or control exceeded these levels as well as the 
percentage of subjects who achieved “clinically detectable 
differences.”
Description of studies
The search strategy identiﬁ  ed 14 trials, 10 placebo-controlled, 
meeting inclusion criteria (Table 1). (Rollema et al 1991; 
Christensen et al 1993; Janknegt and Chapple 1993; Chapple 
et al 1994; Fawzy et al 1995; Gillenwater et al 1995; Kaplan 
et al 1995; Roehrborn and Siegel 1996; Akan et al 1998; 
Andersen et al 2000; Kirby 2003; Kirby et al 2003; McConnell 
et al 2003; de Reijke and Klarskov 2004; Lee et al 2005). Two 
of the placebo-controlled trials had finasteride, a 5-alpha 
(5-α) reductase inhibitor, monotherapy, and combined 
doxazosin/ﬁ  nasteride (combination therapy) arms (Kirby 
et al 2003; McConnell et al 2003). The report by Roehrborn 
(Roehrborn and Siegel 1996) was a pooled analysis of 3 
double-blinded, placebo-controlled trials, 2 published (Fawzy 
et al 1995; Gillenwater et al 1995) and 1 unpublished. Not 
shown in Table 1 is a meta-analysis of 5 placebo-controlled Clinical Interventions in Aging 2006:1(4) 391
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Table 1 Description of randomized trials of doxazosin for treatment of LUTS suggestive of benign prostatic hyperplasia
 Doxazosin,        Study
Reference/Study design  mg/day(n)  Control (n)  Description of subjects, inclusion criteria  duration*
Akan et al 1998  
Fixed-dose, blinding  4 mg(24)  Placebo(19)  Turkish men >48 years old (mean 62) with  6 weeks 
unclear      symptoms of “prostatism” identiﬁ  ed by global
     physician  assessment.   
Andersen et al 2000 
Dose-titration to 4 mg or  (1). 1–8 mg  Placebo(155)  Scandinavian men between 50–80 years old   17 weeks
8 mg, double-blinded      (318);    (mean 65) with BPH: IPSS† score ≥12; peak urine 
  (2). GITS* 4    ﬂ  ow [PUF] of 5–15 mL/s in a total voided
      or 8 mg (311)    volume [TVV] of ≥150 mLs.
Chapple et al 1994   
Dose-titration,  1–4 mg(67)  Placebo (68)  Normotensive/mildly hypertensive British men,  14 weeks 
double-blinded      mean age 67, white race 88%, with symptomatic
     urodynamically  conﬁ  rmed benign prostatic
      obstruction: PUF <15 mL/s with a TVV > 150 mLs.
Christensen et al 1993 
Fixed-dose, double-blinded  4 mg (52)  Placebo (48)  Normotensive/mildly hypertensive Danish men,  10 weeks
      mean age 67, with symptomatic (moderate-
      severe symptoms) BPH who were candidates
      for transurethral resection of the prostate.
Fawzy et al 1995      
Dose-titration to 2 mg, 4 mg,  1–8 mg (50)  Placebo (50)   Normotensive American men, age >45 years  17 weeks
or 8 mg, double-blinded      (mean 62), white race 96%, with symptomatic
     (BPH:  AUA†  score  ≥10; PUF of 5–15 mL/s
       in a TVV of 125–500 mLs.
Gillenwater et al 1995 
Fixed-dose, double-blinded  2 mg, 4 mg,  Placebo (49)  American men with mild to moderate essential   16 weeks
  8 mg, 12 mg    hypertension, 45 years or older (mean 64) with
  (199)    symptomatic BPH (PUF of 5–15 mL/s in a TVV   
      150–500 mLs; post-void residual volume
      <200 mLs; daytime micturition ≥4 and nocturia ≥2.
Kirby et al 2003 [PREDICT]  
Dose-titration to 4 or 8 mg,  (1) 1–8 mg (275);  (1) Placebo (270);  European men between with 50 and 80 years  54 weeks
double-blinded  (2) Combined   (2) Finasteride   (mean 64) with moderate to severe BPH: 
     with  ﬁ  nasteride        5 mg (264)   IPSS score ≥12; PUF of 5–15 mL/s; and enlarged
        5 mg (286)    prostate determined by digital rectal exam (DRE).
McConnell et al 2003 
[MTOPS] Dose-titration  (1) 1–8 mg (756);  (1) Placebo (737);  American men, 50 years or older (mean 63),   234 weeks
to 4 mg or 8 mg,  (2) Combined  (2) Finasteride   white race 82%, black race 9%, Hispanic 7%,   mean
double-blinded      with ﬁ  nasteride      5 mg (768)  with moderate to severe BPH: AUA score ≥8;   follow-up
      5 mg (786)    PUF of 4–15 mL/s; TVV ≥125 mLs.
Roehrborn and Siegel 1996 † 
Fixed-dose,  0.5 mg, 1 mg,  Placebo(98 total)  Normotensive men, age ≥45 years with  16 weeks
double-blinded  2 mg, 4mg(98)    symptomatic BPH: AUA score ≥10; PUF of  
      5–15 mL/s in a TVV of 125–500 mL; 
  post-void residual volume £250 mLs.
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 Doxazosin,      Study
Reference/Study design  mg/day(n)  Control (n)  Description of subjects, inclusion criteria  duration*
Rollema et al 1991  
Fixed-dose,  1 mg, 2 mg,  Placebo(17)  Normotensive or mildly hypertensive  5 weeks
double-blinded  4 mg(50)    Dutch men between 50–80 years   
      (mean 65) with >2 symptoms of 
     “prostatism:”  unidentiﬁ  ed symptom score
      >6 out of 15; PUF <10 mL/s.
de Reijke and 
Klarskov 2004   mean dose  Alfuzosin  Dutch and Scandinavian men aged 49–80 years  16 weeks
  6.1 mg(105)  mean dose  (mean 63) with moderate to severe BPH: IPSS   
   8.8  mg(105)  score  ≥12; PUF of 5–15 mL/s in a TVV
     ≥150 mL; and enlarged prostate
      determined by DRE. 
Kaplan et al 1995 
Fixed-dose  4 mg (22)  Terazosin  American normotensive men aged 50–80  234 
    5 mg; (21)  years (mean 59.6) with symptomatic  weeks 
      BPH: Boyarsky score ≥8; PUF of  mean
      5–15 mL/s in a TVV of 150 mLs.  follow-up
Kirby 2003  
Crossover, dose-titration,   GITS 4 mg or   Tamsulosin  British hypertensive men aged 50–80 years  20 weeks
double-blinded  8 mg (48)  0.4 or  (mean 65), white race 98%, with symptomatic 
    0.8 mg(50)  BPH: IPSS score ≥12; PUF of 5–15 mL/s in a 
      TVV of 150 mLs; and enlarged prostate
      determined by DRE.
Lee et al 2005  
Fixed-dose, double-blinded  (1) GITS 4 mg    Korean men aged 50–80 years (mean 66)   8 weeks
       (76)    with overactive bladder for ≥6 months and 
  (2) Combined    urodynamically proven bladder outlet
       with propiverine    obstruction (Abrams-Grifﬁ  th score ≥20). 
       20 mg (142)   
Note: *Includes run-in periods; † A pooled analysis of 3 trials; Fawzy (all subjects from the study with follow-up efﬁ  cacy data), Gillenwater (4 mg, 8 mg and placebo), and an 
unpublished study. The unpublished study 3 characteristics are presented here.
Abbreviations: GITS, gastrointestinal therapeutic system.
studies (Janknegt and Chapple 1993), 3 published (Rollema 
et al 1991; Christensen et al 1993; Chapple et al 1994) and 
2 unpublished included only in the safety analyses. Three 
studies compared doxazosin with α1–blockers alfuzosin 
(de Reijke and Klarskov 2004), terazosin (Kaplan et al 
1995), and tamsulosin (Kirby 2003). Treatment allocation 
was unclear in all but 1 study (McConnell et al 2003). All 
studies were double-blinded with the exception of the 2 trials 
in which blinding methods were not stated (Akan et al 1998) 
or not used (Kaplan et al 1995). All studies were published 
in English.
Baseline characteristics
A total of 6261 men (doxazosin n = 2413, placebo n = 1460, 
active control n = 1208, doxazosin-ﬁ  nasteride combination 
therapy n = 1054, doxazosin-propiverine combination 
therapy n = 152) were randomized. The mean age was 
64 years. The dose of doxazosin was generally 4 mg or 
8 mg, either titrated to response or a ﬁ  xed dose. Three stud-
ies assessed the efﬁ  cacy of controlled release gastrointes-
tinal therapeutic system (GITS) formulation of doxazosin, 
a placebo-controlled study with a standard formulation 
treatment arm, a crossover study versus tamsulosin, and a 
study comparing doxazosin-propiverine combination with 
doxazosin montherapy (Andersen et al 2000; Kirby 2003; 
Lee et al 2005). Study duration ranged from 5 weeks to 
4.5 years with 3 trials lasting at least one year. Of the four 
placebo-controlled trials reporting racial characteristics, 
86% of the participants were white, 7% black (Chapple et al 
1994; Fawzy et al 1995; Andersen et al 2000; McConnell 
et al 2003). Men in the one active-controlled trial that 
reported racial characteristics were overwhelmingly white Clinical Interventions in Aging 2006:1(4) 393
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(Kirby 2003). Two studies speciﬁ  cally recruited men with 
mild to moderate essential HTN (Gillenwater et al 1995; 
Kirby 2003). One trial enrolled men with overactive bladder 
(OAB) with concomitant BPH (Lee et al 2005). 
Severity of LUTS at baseline did not differ by treatment 
group based on symptom scores and peak urine ﬂ  ow rates. 
The mean baseline IPSS in 5 placebo-controlled trials was 
17.1 points, indicative of moderate BPH. The mean baseline 
peak urine ﬂ  ow was 10.1 milliliters per second (mL/sec) in 
6 placebo-controlled trials and the trial versus terazosin. 
Results
Doxazosin vs placebo (n = 10 studies)
Urinary symptom scores
Statistically signiﬁ  cant improvements in urinary symptom scores 
were reported in 6 trials (Fawzy et al 1995; Gillenwater et al 
1995; Akan et al 1998; Andersen et al 2000; Kirby et al 2003; 
McConnell et al 2003), shown in Table 2. The IPSS was used 
to evaluate LUTS in 5037 men (Fawzy et al 1995; Akan et al 
1998; Andersen et al 2000; Kirby et al 2003; McConnell 
et al 2003). Improvements in the IPSS were maintained in 
the 2 dose-titration studies 1 year or longer in duration. 
The Medical Therapy of Prostatic Symptoms (MTOPS) tri-
al was the largest and longest study conducted (McConnell et al 
2003). The goal of MTOPS was to determine if combination 
medical therapy with an α1–blocker and a 5-α reductase 
inhibitor was superior to placebo or either drug alone at 
improving both baseline symptoms and preventing disease 
progress as determined by a worsening IPSS score of at least 
4 points and/or need for surgical intervention. The mean 
change from baseline over 4 years was –6.6 points (39% 
improvement) for doxazosin compared with –4.9 points 
(29%) placebo (McConnell et al 2003). When compared 
with placebo, the mean change in IPSS scores for patients 
randomized to receive doxazosin (WMD = –1.7 points, 
p < 0.001) with this level of LUTS did not achieve a level 
previously determined to be noticeable by patients (ie, at least 
3 point improvement). The yearlong Prospective European 
Doxazosin and Combination Therapy (PREDICT) trial 
reported a mean change from baseline of –8.3 points (49% 
improvement) for doxazosin versus –5.7 points (33%) for 
placebo (Kirby et al 2003). Similar to the MTOPS ﬁ  ndings, 
the average change due to doxazosin compared with placebo 
in the PREDICT trial did not reach a clinically noticeable 
level (WMD = –2.6 points, p < 0.05).
Mean change in urinary symptom scale scores varied 
in studies that were “mid-length duration” (ie, >12 weeks 
<1 year). Modiﬁ  ed unvalidated Boyarsky symptom scores 
were used in 2 studies involving 383 men (Chapple et al 1994; 
Gillenwater et al 1995). The ﬁ  xed-dose study by Gillenwater 
found only the 4 mg dose statistically superior to placebo in 
improving both severity and bother scores (Gillenwater et al 
1995). Roehrborn and Siegel transformed different symptom 
indices (AUA and Boyarsky) to produce a homogeneous 
pool of symptom and bother data in their pooled analysis 
(Roehrborn and Siegel 1996). Doxazosin resulted in 
signiﬁ  cantly greater improvements in symptom severity 
and bother versus placebo (Roehrborn and Siegel 1996). 
Doxazosin GITS was as effective as standard doxazosin in 
improving symptoms compared with placebo (symptom score 
reductions from baseline for Doxazosin GITS, Doxazosin and 
Placebo = 8.0, 8.4, and 6.0 points respectively) (Andersen 
et al 2000). None of the improvements reached a clinically 
detectable difference compared with placebo.
Peak urinary ﬂ  ow
Doxazosin signiﬁ  cantly improved peak urinary ﬂ  ow (PUF) in 
6 studies compared with placebo (Fawzy et al 1995; Gillenwater 
et al 1995; Akan et al 1998; Andersen et al 2000; Kirby et al 
2003; McConnell et al 2003) (Table 2). The percentage increases 
in peak ﬂ  ow for the mid-term trials were, on average, between 
20%–30%. Long-term maintenance of these improvements was 
shown in MTOPS and PREDICT with MTOPS demonstrating 
39% increase in peak ﬂ  ow after 4 years (McConnell et al 2003). 
Overall, mean change for PUF from baseline for doxazosin 
ranged from 1.5–3.6 milliliters per second (mL/sec). Mean 
change for placebo ranged from –0.3 mL/sec to 1.8, with 
improvements from –18% to 18%. The WMD from baseline 
for three studies, including the Roehrborn analysis that 
incorporated data from the Fawzy and Gillenwater trials, was 
1.6 mL/sec (95% CI, 1.2–2.1) versus placebo (Roehrborn 
and Siegel 1996; Andersen et al 2000; Kirby et al 2003). 
The clinical importance of this is not known.
Doxazosin vs ﬁ  nasteride (n = 2 studies)
MTOPS and PREDICT also compared the effect of 
doxazosin with ﬁ  nasteride 5 mg monotherapy. Doxazosin 
was signiﬁ  cantly more effective than ﬁ  nasteride in improving 
IPSS scores and PUF versus ﬁ  nasteride at 1 year (Kirby 
et al 2003a; McConnell et al 2003) At year 4, there was no 
difference in peak ﬂ  ow between doxazosin and ﬁ  nasteride 
(McConnell et al 2003).Clinical Interventions in Aging 2006:1(4) 394
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Table 2 Outcomes data from individual studies of doxazosin for treatment of LUTS suggestive of benign prostatic hyperplasia
Reference/N (#)  Symptom score (SS): points    Peak Flow Rate: mL/s  Change %
     or   Change %      (increase) 
   Symptoms Improvement  (decrease)      vs baseline/ 
       vs.  baseline/     p-value  between 
      mean   p-value between    mean   placebo/  
Drug  (mg/d)/Control  baseline* change  placebo/control  baseline* change  control 
Placebo-controlled trials, long-term study duration (≥52 weeks)
Kirby N = 1095  IPSS**
Doxazosin (D) 4 mg or  17.1 ± 4.2 (SD)  –8.3 ± 0.4 (SE)  –49%/<0.05 vs. F, P  10.4 ± 2.5 (SD)  3.6 ± 0.3   35%/<0.05 vs F, P
8 mg 
Finasteride 5 mg (F)  17.1 ± 4.4 (SD)  –6.6 ± 0.4  –39%  10.2 ± 2.5 (SD)   1.8 ± 0.3  18%
Combination D+F  17.3 ± 4.7 (SD)  –8.5 ± 0.4  –49%/<0.05 vs. F, P  10.4 ± 2.7 (SD)   3.8 ± 0.3  37%/<0.05 vs. F, P
Placebo (P)  17.2 ± 4.5 (SD)  –5.7 ± 0.4  –33%  10.8 ± 2.5 (SD)   1.4 ± 0.3  13%
MTOPS N = 3047  AUA** 
Doxazosin 4 mg or 8 mg  17.0 ± 5.8 (SD)  –6.6  –39%/<0.001 vs. F, P  10.3 ± 2.5 (SD)  4.0  39%/<0.001 vs F, P
Finasteride 5 mg   17.6 ± 5.9 (SD)   –5.6  –32%  10.5 ± 2.5 (SD)  3.2  30%
Combination D+F  16.8 ± 5.8 (SD)   –7.4  –44%/<0.001 vs. F, P,  10.6 ± 2.5 (SD)  5.1  48%/<0.001 vs. F, P 
          0.035 vs. D    0.002 vs. D
Placebo (P)  16.8 ± 5.9 (SD)   –4.9  –29%  10.5 ± 2.6 (SD)   nr†
Placebo-controlled trials, mid-term study duration (>12 weeks <52 weeks)
Andersen N = 795  IPSS
Doxazosin 4 mg or 8 mg  17.8 ± 4.5  –8.4 ± 0.3  –47%/<0.001  10.0 ± 2.8  2.2 ± 0.2  22%/<0.001
Dox.–GITS†† 4 mg or   17.7 ± 4.3  –8.0 ± 0.3  –45%/<0.001  10.3 ± 2.6  2.6 ± 0.2  25%/<0.001
8 mg
Placebo  18.0 ± 4.3  –6.0 ± 0.4  –33%  9.9 ± 2.6  0.8 ± 0.3  8%
Chapple N = 135  Modiﬁ  ed Boyarsky
Doxazosin 4 mg   “Slight differences” between   9.1 ± 0.5   (SE)  2.6 ± 0.7  29%/0.09
    doxazosin and placebo in
    both obstructive and  
Placebo   irritative symptom scores.  9.1 ± 0.5    1.1 ± 0.6  12%
Fawzy N = 100  AUA
Doxazosin 2 mg,   14.2 ± 3.6(SD)  –5.7  –39%/<0.001  9.7 ± 2.5  2.9  30%/<0.01
4mg or 8 mg
Placebo  15.6 ± 3.3  –2.5  –17%  9.9 ± 2.4  0.7  7%
Gillenwater N = 248  Modiﬁ  ed Boyarsky–Severity score (total)    
Doxazosin 2 mg  28.2 ± 3.6(SD)  –2.8  –10%/ns‡  nr   1.5  –/ns
Doxazosin 4 mg  30.0 ± 4.6  –5.0  –17%/<0.01  nr  2.3  –/<0.05 
Doxazosin 8 mg  30.0 ± 4.0   –4.2  –14%/<0.05  nr  3.3  –/<0.01 
Doxazosin 12 mg  29.0 ± 4.6   –3.6  –12%/ns  nr  3.6  –/<0.01 
Placebo  28.0 ± 5.0  –2.5  –9%  nr  0.1  –
   Modiﬁ  ed Boyarsky-Bothersomeness score (total)
Doxazosin 2 mg  37.1 ± 5.8(SD)  –3.4  –9%/ns 
Doxazosin 4 mg  38.1 ± 5.8   –5.3  –14%/<0.05 
Doxazosin 8 mg  37.4 ± 6.6   –4.7  –13%/ns 
Doxazosin 12 mg  37.4 ± 5.6   –4.9  –13%/ns 
Placebo  36.3 ± 6.5  –3.0  –8%
Roehrborn N = 339 (A pooled analysis that included data Fawzy (dose titration), Gillenwater and unpublished data from Pﬁ  zer 
(both ﬁ  xed-dose studies)
    Based on the AUA and Boyarsky (Severity) 
    symptom scores = 100 points
Doxazosin 4 or 8 mg  47.1 ± 0.9 (SE)   –16.4  –35%/0.0001  10.0 ± 0.2 (SE)  2.2 ± 0.3  22%/0.0017
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Reference/N (#)  Symptom score (SS): points    Peak Flow Rate: mL/s  Change % 
     or   Change %      (increase) 
   Symptoms Improvement  (decrease)      vs baseline/
       vs.  baseline/     p-value  between
      mean   p-value between    mean   placebo/ 
Drug  (mg/d)/Control  baseline* change  placebo/control  baseline* change  control 
Placebo  48.2 ± 1.1  –9.8  –20%  10.0 ± 0.2  0.9 ± 0.3  9%
Placebo-controlled trials, short-term study duration (<12 weeks)
Akan N = 43  IPSS
Doxazosin 4 mg   18  –10  –56%/<0.05  10  3.2  32%/<0.05
Placebo    18 –7  –39%  10 1.8    18%     
Christensen N = 100  Patient subjective overall assessment
Doxazosin 4 mg  79% reporting improvement  0.001  7.6 ± 3.7 (SD)  1.5  20%/0.11
Placebo  44% reporting improvement    7.5 ± 3.5  –0.3  –4%
Rollema N = 67  Symptom score not identiﬁ  ed      
Doxazosin 1 mg  7.8  –1.2  –15%/nr  6.0  1.8  30%/nr   
  Doxazosin 2 mg  7.8  –1.6  –21%  6.5  3.1  48%     
Doxazosin 4 mg  7.8  –1.3  –17%  8.2  1.1  13%
Placebo  8.1 –1.5  –19%  8.6 –0.8  –9%     
Active-controlled trials: versus α1-receptor antagonists (n = 3)
de Reijke N = 210  IPSS
Doxazosin mean 6.1 mg  19.1 ± 5.2 (SD)   –9.2 ± 0.6 (SE)  –48%/<0.05  10.0 ± 3.3  2.5 ± 0.4  25%/ns
Alfuzosin mean 8.8 mg  18.0 ± 4.8   –7.4 ± 0.6  –41%  10.6 ± 3.1  2.8 ± 0.4  26% 
 
Kaplan N = 43  Boyarsky –Total
Doxazosin 4 mg (AM)  11.6  –4.9  –42%/ns for all  9.0  2.8  31%/ns for all
       groups     groups 
Doxazosin 4 mg (PM)  12.0  –5.0  –42%  9.2  3.1  34%   
Terazosin 5 mg (AM)  12.1  –4.6  –38%  9.2  3.0  33%   
Terazosin 5 mg (PM)  11.5  –5.4  –47%  8.9  3.1  35%     
Kirby N = 52  IPSS
Dox.–GITS 4   16.4 ± 6.4 (SD)   –8.0 ± 0.5  –50%/0.019  10.4 ± 3.14  2.6 ± 0.4  25%/0.089
or 8 mg
Tamsulosin 0.4 or  16.1 ± 6.8  –6.4 ± 0.5   –40%  10.3 ± 4.35  1.7 ± 0.4  17%
 0.8 mg
Lee N = 228  IPSS
Dox.-GITS 4 mg  20.6 ± 7.2 (SD)  –7.3  –35%/ns  10.5 ± 4.2  1.7  16%/ns
Combination D+  22.0 ± 7.3 (SD)   –7.4  –34%   10.4 ± 4.3  1.0  10%
Propiverine 20 mg
Note: *±, Standard deviation (SD) or Standard error (SE); ** International Prostate Symptom Score is equivalent to the American Urological Association Symptom Score 
(AUA-SS) in the United States; † nr, not reported; ††GITS, gastrointestinal therapeutic system,  ‡ ns, not statistically signiﬁ  cant.
Combination therapy (n = 2 studies)
Combination ﬁ  nasteride plus doxazosin therapy provided 
similar improvement in symptom scores and peak flow 
rates compared with doxazosin alone at 1 year (Kirby 
et al 2003; McConnell et al 2003). However, over a 4-year 
period, improvements in urinary symptoms and PUF were 
significantly greater with combination therapy versus 
doxazosin or finasteride alone (McConnell et al 2003). Mean 
change for combination therapy was –7.4 IPSS points com-
pared with –6.6 (WMD = –0.8 points), –5.6, and –4.9 points 
for doxazosin, finasteride, and placebo, respectively. 
The median change from baseline for peak ﬂ  ow rate for Clinical Interventions in Aging 2006:1(4) 396
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combination therapy was 3.7 mL/sec (mean 5.1), 2.5 mL/sec 
(mean 4.0) for doxazosin, 2.2 mL/sec (mean 3.2) for ﬁ  nas-
teride, and 1.4 mL/sec for placebo. 
The primary outcome measure of the MTOPS trial 
was the effect of doxazosin, ﬁ  nasteride, and combination 
therapy on the overall clinical progression of BPH. Clinical 
progression was deﬁ  ned as any occurrence of the following 
items: 1) increase of at least 4 AUA points from baseline; 
2) acute urinary retention; 3) urinary incontinence; 4) renal 
insufﬁ  ciency; or 5) recurrent urinary tract infections. Com-
bination therapy signiﬁ  cantly reduced the risk of overall 
clinical progression of BPH compared with the monthera-
pies and placebo (p < 0.001 for all groups). There were 
42 incidences of clinical progression for the combination 
therapy group, 73 for doxazosin, 78 for ﬁ  nasteride, and 
122 for placebo at a mean follow-up of 4 years. Signiﬁ  cant 
reductions were also observed for doxazosin and ﬁ  nasteride 
monotherapy versus placebo. Reduction in risk versus pla-
cebo was 66%, 39%, and 34% for combination therapy, 
doxazosin, and finasteride, respectively. The vast majority 
of “Clinical progression events” were due to increase of at 
least 4 AUA points from baseline. Among the men taking 
placebo, there were 122 cumulative clinical progression 
event (97/122 were due to at least a 4 point increase in AUA 
symptom score-item 1) compared with 42 events (36 item 1) 
for combination therapy (5.3%, absolute risk reduction (ARR) 
versus placebo 11.3%), 73 events (55 item 1) for doxazosin 
(9.7%, ARR 6.9%), and 78 events (65 item 1) for ﬁ  nasteride 
(10.2%, ARR 6.4%). Four cases of urinary retention (<1% of 
subjects, ARR 1.9%) were reported for combination therapy 
group compared with 6 for ﬁ  nasteride (<1%, ARR 1.7%), 9 for 
doxazosin (1.2%, ARR 1.3%), and 18 for placebo (2.4%). 
Subgroup analysis suggested that effectiveness of combina-
tion therapy was associated with prostate volume as measured 
by PSA levels or transrectal ultrasound. For example, in the 
20% and 30% of men with baseline PSA 4 ng/ml or greater 
or ultrasound prostate volume greater than 40 ml the number 
needed to treat at 4.5 years was 4.9 and 4.7 respectively, com-
pared with 8.4 in the entire cohort (Kaplan et al 2006)
Combination therapy reduced the need for minimally 
invasive therapy (eg, transurethral prostatectomy, laser 
surgery, or microwave thermotherapy) and risk of urinary 
retention compared with doxazosin. However, the absolute 
improvement versus placebo at 4 years was 3.5% for the 
combination therapy group compared with 3.2% and 1.6% 
for ﬁ  nasteride and doxazosin monotherapy, respectively 
(McConnell et al 2003). 
Doxazosin vs other α1–blockers 
(n = 3 studies)
Treatment with doxazosin resulted in a greater decrease in 
IPSS score from baseline compared with alfuzosin, –9.2 points 
versus –7.4 points (p = 0.036) (de Reijke and Klarskov 2004). 
Doxazosin was not more effective in improving PUF over the 
14-week study period. Doxazosin-GITS produced a greater 
improvement versus tamsulosin in the IPSS (–8.0 points 
vs –6.4 points, p = 0.019) but was not signiﬁ  cantly more 
effective in improving PUF at the end of the 20-week study 
period (Kirby 2003). Doxazosin 4 mg and terazosin 5 mg 
were similar in efﬁ  cacy in a study investigating the effect 
of dosing schedule and safety of the two α1–blockers over 
a mean follow-up of 42 weeks (Kaplan et al 1995). 
Doxazosin vs Doxazosin plus
Propiverine (n = 1 study)
Combined antimuscarinic propiverine and doxazosin GITS 
therapy was effective and relatively safe in treating men 
with OAB and BPH (Lee et al 2005). Both combination and 
doxazosin GITS monotherapy improved total IPSS, peak 
ﬂ  ow rate, urinary frequency and average micturition volume. 
Improvements in storage symptoms and urgency IPSS 
subscales were signiﬁ  cantly greater in subjects treated with 
combination therapy. 
Withdrawals and adverse events
Withdrawal from treatment and adverse event data for the 
placebo-controlled trials is summarized in Table 3. Men receiving 
doxazosin were less likely to stop treatment (15%) than men on 
placebo (20%) (Christensen et al 1993; Chapple et al 1994; Fawzy 
et al 1995; Gillenwater et al 1995; Andersen et al 2000; Kirby 
et al 2003; McConnell et al 2003). Withdrawals related to adverse 
events were higher in men in the doxazosin group (RR = 1.9; 95% 
CI, 0.9–4.0) and were often related to cardiovascular events such 
as dizziness although instances of hypotension were rare. 
Most placebo-controlled trials reported speciﬁ  c adverse 
events data. The incidence of dizziness, asthenia, and postural 
hypotension were signiﬁ  cantly greater compared with men in 
the placebo and ﬁ  nasteride groups. It is unclear from most of 
the trials whether the postural hypotension was symptomatic 
or asymptomatic. Rates of dizziness, asthenia, and postural 
hypotension were 11%, 6%, and 2% compared with 7%, 
3%, and <1% for placebo. Reports of hypotension and som-
nolence, although small and infrequent, were more likely to 
occur in men treated with doxazosin (Janknegt and Chapple 
1993; Chapple et al 1994; Fawzy et al 1995; Kirby et al 2003; Clinical Interventions in Aging 2006:1(4) 397
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Table 3 Withdrawals from treatment and adverse events: Number of men reporting
        Number  of    Relative 
        Studies  Risk  Ratio 
Adverse events  n/N  %  n/N  %  Reporting  [95% CI]
Versus Placebo  Doxazosin   Placebo
Withdrawals: all causes  198/1282  15.4  125/640  19.5  6  0.93 [0.64 to 1.35]
Withdrawals: due to AEs  108/1282  8.4  39/640  6.1  6  1.88 [0.88 to 4.01]
Any AE  265/536  49.4  98/268  36.6    3*  1.35 [1.12 to 1.62]
Dizziness  163/1450  11.2  49/693  7.1    5*  1.92 [1.40 to 2.61]
Headache  99/1474  6.7  70/714  9.8    6*  0.81 [0.39 to 1.72]
Asthenia  93/1450  6.4  17/693  2.5    5*  3.33 [1.97 to 5.61]
Postural hypotension  32/1400  2.3  6/643  <1  4  2.72 [1.21 to 6.15]
Somnolence  21/471  4.5  8/412  1.9  2  2.31 [1.02 to 5.21]
Impotence  16/275  5.8  9/269  3.3  1  1.71 [0.77 to 3.79]
Versus ﬁ  nasteride**  Doxazosin   Finasteride    
Withdrawals: all causes  282/1031  27.4  265/1032  25.7  2  1.05 [0.87 to 1.26]
Withdrawals: due to AEs  32/275  11.6  34/264  12.9  1  0.90 [0.57 to 1.42]
Dizziness  43/275  15.6  21/264  8.0  1  1.97 [1.20 to 3.22]
Asthenia  29/275  10.5  11/264  4.2  1  2.53 [1.29 to 4.96]
Postural hypotension  16/275  5.8  2/264  <1  1  7.68 [1.78 to 33.08]
Impotence  16/275  5.8  13/264  4.9  1  1.18 [0.58 to 2.4]
Combination therapy versus placebo**  Combination therapy    Placebo
Withdrawals: all causes  89/286  31.1  76/270  28.1  1  1.11 [0.85 to 1.43]
Withdrawals: due to AEs  35/286  12.2  30/270  11.1  1  1.10 [0.70 to 1.74]
Dizziness  39/286  13.6  20/269   7.4  1  1.83 [1.10 to 3.06]
Asthenia  29/286  9.1  11/269   4.1  1  2.48 [1.26 to 4.86]
Postural hypotension  8/286  2.8  4/269  1.5  1  1.88 [0.57 to 6.17]
Impotence  30/286  10.5  9/269  3.3  1  3.14 [1.52 to 6.48]
Versus alfuzosin**  Doxazosin   Alfuzosin
Discontinuations: all causes  12/105  14.3  18/105  17.1  1  0.67 [0.34 to 1.31]
Discontinuations: due to AEs  12/105  14.3   7/105  6.7  1  1.71 [0.70 to 4.18]
Dizziness  14/99  14.1  11/93  11.8  1  1.20 [0.57 to 2.50]
Asthenia  5/99  5.1  5/93  5.4  1  0.94 [0.28 to 3.14]
Postural hypotension  2/99  2.0  3/93  3.2  1  0.63 [0.11 to 3.66]
Impotence  0/99  0.0  1/93  1.1  1  0.31 [0.01 to 7.60] 
 
Versus tamsulosin**   Doxazosin-GITS   Tamsulosin    
(crossover study)
Any AE  38/48  79.2  39/50  78.0  1  1.01 [0.83 to 1.25]
Treatment-related AE  18/48  37.5  20/50  40.0  1  0.94 [0.57 to 1.54]
Dizziness  8/48  16.7  8/50  16.0  1  1.04 [0.43 to 2.55]
Asthenia  6/48  12.5  12/50  24.0  1  0.52 [0.21 to 1.28]
Headache  6/48  12.5  8/50  16.0  1  0.78 [0.29 to 2.08]
Hypotension  4/48  8.3  2/50   0.4  1  2.08 [0.40 to 10.85]
Somnolence  4/48  8.3  2/50  0.4  1  2.08 [0.40 to 10.85]
Retrograde ejaculation  0/48  0.0  2/50  0.4  1   
Versus terazosin†  Doxazosin   Terazosin    
Discontinuations: all causes  3/22  13.6  5/21  23.8  1  0.57 [0.16 to 2.10]
Discontinuations: 
due to adverse events  3/22  13.6  5/21  23.8  1  0.57 [0.16 to 2.10]
Dizziness  1/22  4.5  3/21  14.3  1  0.32 [0.04 to 2.82]
Headache  1/22  4.5  1/21  4.8  1  0.95 [0.06 to 14.30]
Continued...Clinical Interventions in Aging 2006:1(4) 398
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         Number  of    Relative 
         Studies  Risk  Ratio 
Adverse events  n / N  %  n / N  %  Reporting  [95% CI]
Versus combination doxazosin and       Combination
propiverine therapy  Doxazosin   therapy
Discontinuations: all causes†  9/76  11.8  21/152  13.8  1  0.86 [0.41 to 1.78]
Discontinuations: 
due to adverse events  1/69  1.4  7/142  4.9  1  0.29 [0.04 to 2.34]
Dry mouth  4/69  5.8  26/142  18.3  1  0.32 [0.12 to 0.87]
Dizziness unclear    8/142  5.6  1
Difﬁ  cult voiding  1/69  1.4  4/142  2.8  1  0.51 [0.06 to 4.52]
Constipation  0/69  0.0  3/142  2.1  1  0.29 [0.02 to 5.57]
Blurred vision  1/69  1.4  2/142  1.4  1  1.03 [0.09 to 11.15]
Signiﬁ  cant post-void residual 
Volume  0/69  0.0  2/142  1.4  1  0.41 [0.02 to 8.40]
Note: *Includes meta-analysis by Janknegt, pooling studies by Chapple, Christensen, Rollema and 2 unpublished trials; **Includes only men treated with Doxazosin versus 
the respective controls from individual studies; †Includes 17 subjects withdrawing consent and not receiving allocated intervention.
Abbreviations:  AE, adverse event; CI, conﬁ  dence interval. 
McConnell et al 2003). Doxazosin-GITS had fewer adverse 
events compared with standard doxazosin. Dizziness and 
asthenia was reported in 5.7% and 3.2% of men on doxazosin-
GITS compared with 8.4% and 5% of men receiving regular 
release formulations of doxazosin (Andersen et al 2000).
Withdrawal rates primarily related to adverse events were 
comparable between combination therapy with doxazosin 
and ﬁ  nasteride alone (Table 3) (Kirby et al 2003). However, 
the type of adverse event differed between treatment groups. 
Erectile dysfunction reported in PREDICT was signiﬁ  cantly 
greater for combination therapy compared with doxazosin or 
ﬁ  nasteride separately (10.5% vs 5.8% and 4.9%, respectively, 
p < 0.01). In MTOPS, 27% on doxazosin alone discontinued, 
compared with 24% on ﬁ  nasteride and 18% on combination 
therapy (McConnell et al 2003). Dyspnea, abnormal ejacula-
tion, and peripheral edema were reported more frequently in 
men treated with combination therapy. Generally, adverse 
events reported for combination therapy were similar to the 
events common with each monotherapy. Rates of dizziness, 
asthenia, postural hypotension, and somnolence were sig-
niﬁ  cantly greater with doxazosin and combination therapy. 
Erectile dysfunction and decreased libido were reported 
more frequently with use of ﬁ  nasteride and combination 
therapy. 
In the crossover trial evaluating doxazosin-GITS to 
tamsulosin, no subject receiving doxazosin-GITS withdrew 
from the trial because of a treatment-related adverse event 
compared with 2 subjects receiving tamsulosin. The incidence 
of adverse events was generally similar between doxazosin-
GITS and tamsulosin. There were no signiﬁ  cant differences 
in the frequency of adverse events of doxazosin compared 
with alfuzosin and terazosin (Kaplan et al 1995; de Reijke 
and Klarskov 2004). In the doxazosin montherapy versus 
propiverine plus doxazosin trial, two monotherapy and 11 
combination subjects withdrew from treatment prior to study 
completion (Lee et al 2005). Withdrawals due to adverse 
events occurred in one (1.4%) and seven (4.9%) of mono 
and combined therapy subjects, respectively. Dry mouth, a 
common antimuscarinic adverse event, was reported in 18% of 
combination subjects compared with 6% receiving doxazosin 
monotherapy (RR reduction = 0.32; 95% CI, 0.12–0.87). 
Additional information from 
other studies of doxazosin
The AUA Guideline Report on the Management of Benign 
Prostatic Hyperplasia included results from nonrandomized 
studies (AUA 2003). They noted improvements in urinary 
symptoms and ﬂ  ow measures comparable with our ﬁ  ndings 
with an average across all α1–blockers of approximately 2 
to 2.5 points versus placebo (Figures 1 and 2). The median 
dose of doxazosin in analyzed trials was between 6 mg and 
7 mg per day. Doxazosin resulted in an approximately 1–2 
point improvement in the BPH Impact Index with slightly 
less improvement in longer term studies. While there were 
no direct comparison studies, the magnitude of symptom 
improvement reported for doxazosin was less then surgi-
cal or minimally invasive procedures. Analysis of selected 
clinically relevant adverse effects of pharmacologic therapies 
indicates that overall adverse effects and withdrawals are 
similar among α1–blockers, vary in the type of occurrence Clinical Interventions in Aging 2006:1(4) 399
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and only slightly in frequency, especially for symptomatic 
adverse events. 
Of note are results from the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attach Trial (ALLHAT). 
This randomized trial evaluated four classes of pharmacologic 
therapies (including doxazosin) for hypertension in patients 55 
years of age or older. Many enrollees were men and undoubt-
edly some had LUTS of comparable severity with patients 
enrolled in BPH treatment trials. While the effectiveness on 
LUTS and urinary symptoms was not reported, the doxazosin 
arm of the trial was discontinued prematurely due to a higher 
risk of stroke, congestive heart failure and combined cardiovas-
cular events compared with the diuretic chlorthalidone. While 
ALLHAT does not demonstrate that doxazosin is harmful, it 
suggests that use of doxazosin (and likely other alpha blockers) 
to treat both hypertension and LUTS is not warranted. 
Discussion
The evidence from randomized controlled trials demonstrate 
that doxazosin, typically 4 mg/day or 8 mg/day, reduces LUTS 
and improves urinary ﬂ  ow rates compared with placebo and 
ﬁ  nasteride. Efﬁ  cacy was comparable with α1–blockers tera-
zosin, alfuzosin, and tamsulosin. 
The GITS formulation of doxazosin was as effective and 
had slightly fewer adverse effects than the standard formulation 
of doxazosin. However, the average magnitude of improve-
ment compared with placebo did not reach of level previously 
determined to be detectable and is therefore of questionable 
clinical signiﬁ  cance. 
Long-term, doxazosin did reduce the number of men with 
clinical progression of BPH compared with placebo (10% vs 
17%). Combination doxazosin-ﬁ  nasteride therapy reduced 
the percentage of men having clinical progression compared 
with doxazosin (10% vs 5%) and the percent having at least a 
4-point increase in AUA symptom score (7% vs 5%). Com-
bination therapy also reduced the need for invasive treatment 
for BPO though the absolute difference compared with doxa-
zosin was only 2%. The beneﬁ  t appeared to be greatest and 
perhaps limited to men with at least moderately severe urinary 
symptoms and enlarged prostate glands (the latter as measured 
by a PSA >4 and/or a ultrasound volume >40 ml. Dizziness, 
fatigue, and postural hypotension were more frequent with 
doxazosin than with placebo. The combination of doxazosin 
plus ﬁ  nasteride resulted in a higher rate of adverse events then 
for either drug alone.
A limitation of many of the trials reported is the short-
term study duration, with only 2 placebo-controlled studies 
lasting longer than 26 weeks (Kirby et al 2003; McConnell 
et al 2003). Only the MTOPS trial evaluated the long-term 
effect of doxazosin on urinary symptom progression and de-
velopment of urinary retention, renal insufﬁ  ciency, recurrent 
urinary tract infection, and/or need for surgery or a minimally 
invasive technique (McConnell et al 2003). The PREDICT 
study examined the occurrence of acute urinary retention and 
transurethral resection of the prostate in a post-hoc analysis 
(Kirby et al 2003). Similar to MTOPS, PREDICT found no 
beneﬁ  t of combination therapy compared with doxazosin 
alone at 1 year. Thus the currently available evidence suggests 
Figure 1 AUA/IPSS Symptom Index score improvements from baseline for 
medical therapies by duration of follow-up. Missing bars indicate that data were 
not available. Copyright © 2003. Reproduced with permission from Roehrborn CG, 
McConnell JD, Barry MJ, et al. 2003. AUA guideline on the management of benign 
prostatic hyperplasia [online]. Accessed on 28 October 2004. AUA Education and 
Research, Inc. URL: http://auanet.org/guidelines/bph.cfm.
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Figure 2 Peak urine ﬂ  ow-rate improvements for medical therapies from baseline 
by duration of follow-up. Missing bars indicate that data were not available. 
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that doxazosin provides an average improvement in urinary 
symptom scale scores of approximately 2 points versus placebo, 
which is maintained over 4 years. It reduces the percentage 
of men having at least a 4-point increase in urinary symptom 
scale scores by 7% versus placebo and 2% versus ﬁ  nasteride. 
The combination of doxazosin plus ﬁ  nasteride results in an 
additional 0.8 point reduction in the AUA symptom scale 
score, 2% reduction in men having at least a 4 point increase 
in AUA symptom score, and 2% reduction in use of invasive 
therapy due to BPO after 4 years of therapy. 
These beneﬁ  ts need to be balanced against the increased 
medication cost and adverse events associated with combina-
tion therapy. Based on the MTOPS results and the monthly 
drug cost in the US for doxazosin (8 mg) of $24 and finasteride 
of $80, the cost for preventing one episode of at least a 4-point 
progression in AUA symptom scale scores over 4 years would 
be $15 728 for doxazosin (Number needed to treat [NNT] at 
4 years = 13.7), $57 600 for ﬁ  nasteride (NNT at 4 years = 15), 
and $42 718 for combination therapy (NNT at 4 years 
= 8.4). Among men with a serum prostate-speciﬁ  c antigen 
level 4.0 ng per milliliter or greater, medication costs would 
equal to $23 878 for combination therapy (NNT at 4 years 
= 4.7) and $27 616 for ﬁ  nasteride (NNT at 4 years = 7.2) 
(McConnell et al 2003).
Systematic reviews are limited by the quality of evidence 
based on the available information. Adequate concealment 
of treatment of randomization was reported in only one 
study, a validated measure of study quality. Inconsistencies 
(eg, lack of standard deviations or errors) in data report-
ing precluded a pooled analysis of all studies. We were 
also unable to obtain additional data that would have en-
hanced pooling of study results despite multiple attempts to 
contact authors and the manufacturer of doxazosin (Pﬁ  zer 
Pharmaceuticals, New York, NY, USA). Few trials included 
in this systematic review provided racial characteristics and 
those that did were overwhelmingly white. Although race has 
not been shown to compromise efﬁ  cacy (Fulton et al 1995), 
no BPH study has addressed the efﬁ  cacy of doxazosin in 
black men. No studies have directly compared the long-term 
effectiveness, costs, durability, tolerability and satisfaction 
of alpha blockers with other surgical or minimally invasive 
options. 
Conclusion
Doxazosin is generally well tolerated and improves LUTS and 
ﬂ  ow compared with baseline measures in men with sympto-
matic BPH. Efﬁ  cacy was superior to placebo and ﬁ  nasteride 
and comparable with other α1–blockers. Compared with 
placebo, the average symptom improvement may not reach 
clinically noticeable levels though some men may achieve 
detectable beneﬁ  ts and/or have symptom progression pre-
vented. Combination therapy with a 5-α reductase inhibitor 
was superior to doxazosin alone in reducing the risk for 
clinical progression and the need for invasive therapy due 
to BPH although the absolute risk reductions were 5% for 
clinical progression and 2% for invasive therapy. Beneﬁ  t 
from combination therapy was greatest in men with a prostate 
volume greater than 40 mL or a prostate-speciﬁ  c antigen level 
greater than 4.0 ng/mL. 
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